Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

869 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
SETDB1 suppresses NK cell-mediated immunosurveillance in acute myeloid leukemia with granulo-monocytic differentiation.
Chang YH, Yamamoto K, Fujino T, Wang TW, Sugimoto E, Zhang W, Yabushita T, Suzaki K, Pietsch EC, Weir BA, Crescenzo R, Cowley GS, Attar R, Philippar U, Wunderlich M, Mizukawa B, Zheng Y, Enomoto Y, Imai Y, Kitamura T, Goyama S. Chang YH, et al. Among authors: enomoto y. Cell Rep. 2024 Aug 27;43(8):114536. doi: 10.1016/j.celrep.2024.114536. Epub 2024 Aug 2. Cell Rep. 2024. PMID: 39096901 Free article.
Mitotic perturbation is a key mechanism of action of decitabine in myeloid tumor treatment.
Yabushita T, Chinen T, Nishiyama A, Asada S, Shimura R, Isobe T, Yamamoto K, Sato N, Enomoto Y, Tanaka Y, Fukuyama T, Satoh H, Kato K, Saitoh K, Ishikawa T, Soga T, Nannya Y, Fukagawa T, Nakanishi M, Kitagawa D, Kitamura T, Goyama S. Yabushita T, et al. Among authors: enomoto y. Cell Rep. 2023 Sep 26;42(9):113098. doi: 10.1016/j.celrep.2023.113098. Epub 2023 Sep 14. Cell Rep. 2023. PMID: 37714156 Free article.
Hyperactive Natural Killer cells in Rag2 knockout mice inhibit the development of acute myeloid leukemia.
Sugimoto E, Li J, Hayashi Y, Iida K, Asada S, Fukushima T, Tamura M, Shikata S, Zhang W, Yamamoto K, Kawabata KC, Kawase T, Saito T, Yoshida T, Yamazaki S, Kaito Y, Imai Y, Denda T, Ota Y, Fukuyama T, Tanaka Y, Enomoto Y, Kitamura T, Goyama S. Sugimoto E, et al. Among authors: enomoto y. Commun Biol. 2023 Dec 21;6(1):1294. doi: 10.1038/s42003-023-05606-3. Commun Biol. 2023. PMID: 38129572 Free PMC article.
Prostaglandin E2-EP2/EP4 signaling induces immunosuppression in human cancer by impairing bioenergetics and ribosome biogenesis in immune cells.
Punyawatthananukool S, Matsuura R, Wongchang T, Katsurada N, Tsuruyama T, Tajima M, Enomoto Y, Kitamura T, Kawashima M, Toi M, Yamanoi K, Hamanishi J, Hisamori S, Obama K, Charoensawan V, Thumkeo D, Narumiya S. Punyawatthananukool S, et al. Among authors: enomoto y. Nat Commun. 2024 Nov 1;15(1):9464. doi: 10.1038/s41467-024-53706-3. Nat Commun. 2024. PMID: 39487111 Free PMC article.
Prevalence, management, health-care burden, and 90-day outcomes of prolonged mechanical ventilation in the paediatric intensive care unit (LongVentKids): an international, prospective, cross-sectional cohort study.
Kawaguchi A, Fernandez A, Baudin F, Chiusolo F, Lee JH, Brierley J, Colleti J Jr, Reiter K, Won Kim K, Lopez Fernandez Y, Kneyber M, Pons-Òdena M, Napolitano N, Graham RJ, Kawasaki T, Garros D, Garcia Guerra G, Jouvet P; LongVentKids study group. Kawaguchi A, et al. Lancet Child Adolesc Health. 2025 Jan;9(1):37-46. doi: 10.1016/S2352-4642(24)00296-7. Lancet Child Adolesc Health. 2025. PMID: 39701660
Serotonin reuptake inhibitor suppresses the activation of human platelets by a combination of thrombopoietin and collagen through inhibition of Rac and Rho/Rho-kinase.
Tokuda H, Hori T, Onuma T, Enomoto Y, Doi T, Matsushima-Nishiwaki R, Yamaguchi S, Tanabe K, Omura T, Ogura S, Iwama T, Iida H, Kozawa O. Tokuda H, et al. Among authors: enomoto y. Biomed Res. 2024;45(6):231-241. doi: 10.2220/biomedres.45.231. Biomed Res. 2024. PMID: 39581612 Free article.
Physical, but not laboratory, treatment-related adverse events are associated with favorable outcomes of enfortumab vedotin for advanced urothelial carcinoma: A landmark analysis.
Taguchi S, Kawai T, Ambe Y, Kishitani K, Noda M, Kaneko T, Miyakawa J, Nakamura Y, Hoshina H, Obinata D, Yamaguchi K, Kakutani S, Furuya Y, Sato Y, Adachi Y, Sugimoto K, Sato K, Tabata M, Tanaka T, Nara K, Uemura Y, Kamei J, Akiyama Y, Sato Y, Yamada Y, Niimi A, Yamada D, Takada T, Takahashi S, Yamada Y, Miyazaki H, Enomoto Y, Nishimatsu H, Fujimura T, Fukuhara H, Nakagawa T, Takahashi S, Kume H. Taguchi S, et al. Among authors: enomoto y. Int J Urol. 2024 Nov 22. doi: 10.1111/iju.15640. Online ahead of print. Int J Urol. 2024. PMID: 39575880
869 results